Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 12:40 AM
Ignite Modification Date: 2025-12-25 @ 10:50 PM
NCT ID: NCT02002767
Description: The Safety Analysis Set included participants who were enrolled and received at least 1 dose of study drug.
Frequency Threshold: 5
Time Frame: First dose date plus 30 days
Study: NCT02002767
Study Brief: Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Normal Renal Function Participants with normal renal function received velpatasvir 100 mg administered orally with a light breakfast on Day 1. 0 None 0 9 0 9 View
Severe Renal Impairment Participants with severe renal impairment received velpatasvir 100 mg administered orally with a light breakfast on Day 1. 0 None 0 10 2 10 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Vessel puncture site haemorrhage SYSTEMATIC_ASSESSMENT General disorders MedDRA 17 View
Dizziness SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 17 View